Pembrolizumab
Gynecologic Cancer Awareness Month: Regimens extend survival; talc linked to ovarian cancer
September is Gynecologic Cancer Awareness Month.
Q&A: Promising treatment, diagnosis approaches for endometrial cancer
Despite the incidence of endometrial cancer diagnosis increasing annually, several promising approaches for treatment and diagnosis of endometrial cancer have been approved or are in development.
Pembrolizumab regimen extends OS in triple-negative breast cancer
Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.
Benefit of adjuvant pembrolizumab in endometrial cancer varies by mismatch repair status
The addition of pembrolizumab to adjuvant chemotherapy improved DFS for certain women with newly diagnosed high-risk endometrial cancer, according to randomized phase 3 study results presented at ESMO Congress.
Data support pembrolizumab regimen as ‘new standard’ for advanced cervical cancer
The combination of pembrolizumab and chemoradiotherapy significantly improved OS for women with high-risk locally advanced cervical cancer, according to results of a randomized phase 3 trial presented at ESMO Congress.
Combination prolongs PFS in intermediate-stage hepatocellular carcinoma
The addition of lenvatinib and pembrolizumab to transarterial chemoembolization extended PFS for patients with intermediate-stage hepatocellular carcinoma, according to randomized phase 3 study results.
Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’
Ivonescimab significantly improved PFS compared with pembrolizumab as first-line treatment of PD-L1-positive advanced non-small cell lung cancer, according to results of the HARMONi-2 trial.
Phase 3 trials of pembrolizumab for lung cancer, skin cancer halted due to lack of efficacy
Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.
‘Most important study’ in soft tissue sarcomas in decades shows benefit of immunotherapy
CHICAGO — The addition of immunotherapy to radiation therapy and surgery significantly extended DFS for certain patients with soft tissue sarcoma, according to results of a randomized phase 2 trial.